2. Search Result
Search Result
Results for "

detrusor muscle

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0549A
    Flavoxate hydrochloride

    Rec-7-0040; DW61

    		 Calcium Channel Adenosine Receptor mAChR Dopamine Receptor Adrenergic Receptor Cardiovascular Disease Infection Neurological Disease Cancer
    Flavoxate hydrochloride (Rec-7-0040; DW61) is an orally active L-type Ca 2+ channel inhibitor and antispasmodic. Flavoxate hydrochloride inhibits cyclic adenosine monophosphate production by blocking voltage-dependent inward Ba 2+ currents, regulating the brainstem micturition center, and stimulating G protein-coupled receptors. Consequently, Flavoxate hydrochloride induces relaxation of bladder smooth muscle and inhibits isovolumetric rhythmic contractions. Flavoxate hydrochloride effectively increases bladder capacity and alleviates symptoms of urgent urination frequency and pollakiuria caused by overactive bladder. Flavoxate hydrochloride can be used in research on overactive bladder and related voiding dysfunctions .
    Flavoxate hydrochloride
  • HY-15574
    Piboserod
    4 Publications Verification

    SB-207266

    		 5-HT Receptor Cardiovascular Disease
    Piboserod is an orally available selective antagonist of the 5-HT4 receptor, with a Ki value of approximately 0.1 nM for human 5-HT4 receptors. Piboserod can competitively bind to the 5-HT4 receptor and block the activation of the 5-HT4 receptor. Piboserod can inhibit the enhancing effect of 5-HT on the nerve-mediated contraction response of the human bladder detrusor muscle. Piboserod is mainly used in the research of urinary system diseases (such as overactive bladder) and cardiovascular diseases (such as chronic heart failure) .
    Piboserod
  • HY-101396
    ICA-069673
    3 Publications Verification

    		 Potassium Channel Neurological Disease
    ICA-069673 is a KCNQ2/Q3 potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC50s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells .
    ICA-069673
  • HY-103322
    6-Bnz-cAMP sodium salt

    		PKA Potassium Channel Metabolic Disease Cancer
    6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration .
    6-Bnz-cAMP sodium salt
  • HY-108960
    PPADS

    		P2X Receptor Interleukin Related Neurological Disease
    PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC50 values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X1 and P2X3 receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain .
    PPADS
  • HY-14825A
    Tarafenacin D-tartrate

    SVT-40776 D-tartrate

    		 mAChR Inflammation/Immunology
    Tarafenacin (SVT-40776) D-tartrate is an orally active, selective M3 muscarinic receptor (M3 muscarinic receptor) antagonist with 203-fold selectivity over the M2 muscarinic receptor. Tarafenacin D-tartrate does not affect atrial contraction, arterial blood pressure or arterial pressure at high doses. Tarafenacin D-tartrate can be used in the research of overactive bladder .
    Tarafenacin D-tartrate
  • HY-122086
    Prifinium bromide

    		mAChR Neurological Disease
    Prifinium bromide is an anticholinergic drug with anticholinergic and antispasmodic activities, and it exhibits oral activity. Prifinium bromide competitively antagonizes cholinergic receptors and relieves symptoms of spasm or hypermotility in the digestive and urinary tracts, with its anticholinergic activity representing the core mechanism underlying the inhibition of bladder smooth muscle contraction. Prifinium bromide can be used in research related to spasms and diverticular disease .
    Prifinium bromide
  • HY-P3853
    GR 87389

    		Neurokinin Receptor Neurological Disease
    GR 87389 is a potent NK2 receptor antagonist. GR 87389 antagonized GA 64349-induced smooth muscle strips contractions in a competitive manner in the human detrusor, prostate and prostatic urethra .
    GR 87389
  • HY-19228
    FK 584

    		mAChR Calcium Channel Neurological Disease Metabolic Disease
    FK 584 is a potent detrusor muscle contraction inhibitor. FK 584 possesses potent antimuscarinic activity and weak calcium channel blocking activity. FK 584 has demonstrated potent detrusor muscle inhibitory activity in various experimental models with a manageable risk of mydriasis. FK 584 can be used to study overactive bladder (OAB).
    FK 584
  • HY-117717
    (Rac)-SC-31391

    		Prostaglandin Receptor Others
    (Rac)-SC-31391, a prostaglandin analog, is a strong activator of the bladder muscle contractility that enhanced twitch responses elicited by field stimulation in the guinea pig detrusor muscle. (Rac)-SC-31391 contracts human bladder muscle through the activation of PGF2α receptors .
    (Rac)-SC-31391
  • HY-118350
    FR 75513

    		Biochemical Assay Reagents Neurological Disease
    FR 75513 is a 1,1'-biphenyl-2,6-dicarboxylic acid diester series compound that can inhibit the contraction of the detrusor muscle of guinea pig bladder (IC50=3.3 μg/mL). After intravenous injection of FR 75513 into anesthetized rats, it also showed strong inhibitory activity on the detrusor contraction (ID50=0.04 mg/kg).
    FR 75513
  • HY-106415
    Terflavoxate

    		Calcium Channel Neurological Disease
    Terflavoxate is a flavone derivative with spasmolytic properties. Terflavoxate has Ca 2+-antagonistic effect is mainly responsible for Terflavoxate smooth muscle relaxant properties. Terflavoxate has the potential for overactive detrusor research .
    Terflavoxate
  • HY-101586A
    Alvameline maleate

    Lu 25-109 maleate

    		 mAChR Neurological Disease
    Alvameline (Lu 25-109) maleate is a partial agonist of M1 and an antagonist of M2/M3. Alvameline maleate competitively antagonizes contractions induced by ammonium chloride (HY-Y1269) and electrical field stimulation in human detrusor muscle, indicating its potential application in regulating bladder function. Additionally, alvameline maleate can improve cognitive function following traumatic brain injury in rats .
    Alvameline maleate
  • HY-15574R
    Piboserod (Standard)

    SB-207266 (Standard)

    		 5-HT Receptor Reference Standards Cardiovascular Disease
    Piboserod (Standard) is the analytical standard of Piboserod. This product is intended for research and analytical applications. Piboserod is an orally available selective antagonist of the 5-HT4 receptor, with a Ki value of approximately 0.1 nM for human 5-HT4 receptors. Piboserod can competitively bind to the 5-HT4 receptor and block the activation of the 5-HT4 receptor. Piboserod can inhibit the enhancing effect of 5-HT on the nerve-mediated contraction response of the human bladder detrusor muscle. Piboserod is mainly used in the research of urinary system diseases (such as overactive bladder) and cardiovascular diseases (such as chronic heart failure) .
    Piboserod (Standard)
  • HY-14825
    Tarafenacin

    SVT-40776

    		 mAChR Inflammation/Immunology
    Tarafenacin (SVT-40776) is an orally active, selective M3 muscarinic receptor (M3 muscarinic receptor) antagonist with 203-fold selectivity over the M2 muscarinic receptor. Tarafenacin does not affect atrial contraction, arterial blood pressure or arterial pressure at high doses. Tarafenacin can be used in the research of overactive bladder .
    Tarafenacin
  • HY-182599
    RCC-36 hydrochloride

    		Calcium Channel mAChR Neurological Disease
    RCC-36 hydrochloride is an L-type calcium channel inhibitor and competitive muscarinic receptor antagonist. RCC-36 hydrochloride inhibits L-type calcium currents in voltage- and concentration-dependent fashion with no effect on cardiac K + currents. RCC-36 hydrochloride suppresses maximum acetylcholine-induced contractile responses, inhibits detrusor muscle contractions induced by potassium chloride, calcium chloride, and electric field stimulation, including atropine-resistant contractions. RCC-36 hydrochloride can be used for the research of urinary frequency, urinary incontinence, and bladder overactivity .
    RCC-36 hydrochloride
  • HY-101396R
    ICA-069673 (Standard)

    		Potassium Channel Reference Standards Neurological Disease
    ICA-069673 (Standard) is the analytical standard of ICA-069673 (HY-101396). This product is intended for research and analytical applications. ICA-069673 is a KCNQ2/Q3 potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC50s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells .
    ICA-069673 (Standard)
  • HY-183206
    UR 8225

    		Potassium Channel Calcium Channel Cardiovascular Disease Inflammation/Immunology
    UR 8225 is an orally active ATP-sensitive K + channel activator with vasodilator, smooth muscle relaxant, antihypertensive, and bronchodilator activities. UR 8225 induces membrane hyperpolarization by increasing outward K + conductance and reduces Ca 2+ influx through voltage-gated L-type Ca 2+ channels. UR 8225 reduces total peripheral vascular resistance, shortens cardiac action potential duration, inhibits agonist-induced Ca 2+ influx, and stimulates renin release. UR 8225 induces reflex tachycardia but lacks β-adrenergic receptor blocking activity. UR 8225 is widely applicable to research in fields related to hypertension, myocardial ischemia, ventricular fibrillation, and other conditions .
    UR 8225

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: